Anticancer effects of ruthenium-sorafenib complexes in prostate cancer cell lines

Year 2026, Volume: 7 Issue: 2, 261 - 268, 27.03.2026

Dilek Öztürk Civelek , Nida Ceren Çelik , Merve Çavuş , Belma Zengin Kurt

https://izlik.org/JA26AL47CC

Abstract

Aims: To evaluate the cytotoxic and pro-apoptotic activities of newly synthesized ruthenium–sorafenib complexes (Ru1S–Ru8S) in prostate cancer models and to identify a lead candidate for advanced/castration-resistant prostate cancer.
Methods: Ru1S–Ru8S were synthesized as previously described. Cytotoxicity was assessed by MTT in PC3, DU145, LNCaP, and, CCD1079Sk cells after 24 and 48 h exposure to 0.2–100 µM compounds; IC₅₀ values were calculated versus untreated controls. Apoptosis was analyzed in PC3 cells by Annexin V/7-AAD staining and flow cytometry after treatment with Ru1S, Ru3S, Ru4S, or sorafenib at graded concentrations. Molecular modelling examined potential binding interactions of Ru1S.
Results: The complexes displayed cell line- and time-dependent cytotoxicity. At 48 h, Ru1S and Ru4S were among the most active complexes in cancer cells. Ru4S achieved the highest potency in cancer cells but was associated with extensive cell death displaying features consistent with both apoptotic and non-apoptotic processes. Ru1S induced prominent late-stage apoptosis in PC3 cells (comparable to Ru3S) while maintaining substantially lower toxicity in CCD-1079Sk cells. Sorafenib, although highly potent, exhibited considerable toxicity toward CCD-1079Sk cells. Modelling supported an androgen receptor–independent effect for Ru1S.
Conclusion: Ruthenium coordination modulates sorafenib-driven cell-death pathways and may improve in vitro selectivity profiles compared with sorafenib. Ru1S emerged as a lead candidate for further preclinical evaluation in castration-resistant prostate cancer, based on its pro-apoptotic activity in PC3 cells and comparatively lower cytotoxicity in CCD-1079Sk fibroblasts relative to sorafenib.

Keywords

Apoptosis , cytotoxicity , molecular modelling , prostate cancer , ruthenium complexes , sorafenib

Ethical Statement

We, the authors declare that the ethics committee approval is not required for this study.

Supporting Institution

The authors declare that there is no real, potential, or perceived conflict of interest for this article.

Project Number

TUBITAK 217S645

Thanks

This study was supported by TUBITAK 217S645. N.C.C. and M.C. were recipients of TUBITAK 2209.

References

• Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
• Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223-238. doi:10.1016/j.pharmthera.2013.07.003
• Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27(2):327-333. doi:10. 1038/s41391-023-00725-8
• Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with radium-223 in the United States. Prostate Cancer Prostatic Dis. 2025;1-8. doi:10.1038/s41391-025-00969-6
• Yamamoto Y, De Velasco MA, Kura Y, et al. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient prostate cancer. J Transl Med. 2015;13(1):150. doi:10.1186/s12967-015-0509-x
• Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer. 2007;97(11):1480-1485. doi:10.1038/sj.bjc.6604064
• Yan X, Zhou Y, Li H, Jiang G, Sun H. Metallomics and metalloproteomics. In: Reedijk J, Poeppelmeier KR, eds. Comprehensive Inorganic Chemistry III. 3rd ed. Elsevier; 2023:53-76. doi:10.1016/B978-0-12-823144-9.00060-1
• Heffeter P, Atil B, Kryeziu K, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013;49(15):3366-3375. doi:10.1016/j.ejca.2013.05.018
• Zengin Kurt B, Öztürk Civelek D, Çakmak EB, et al. Synthesis of sorafenib–ruthenium complexes, investigation of biological activities and applications in drug delivery systems as an anticancer agent. J Med Chem. 2024;67(6):4463-4482. doi:10.1021/acs.jmedchem.3c01115
• Elsayed SA, Harrypersad S, Sahyon HA, El-Magd MA, Walsby CJ. Ruthenium(II)/(III) DMSO-based complexes of 2-aminophenyl benzimidazole with in vitro and in vivo anticancer activity. Molecules. 2020;25(18):Article 18. doi:10.3390/molecules25184284
• Irace C, Misso G, Capuozzo A, et al. Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action. Sci Rep. 2017; 7(1):45236. doi:10.1038/srep45236
• Pettinari R, Pettinari C, Marchetti F, et al. Arene-ruthenium(II) acylpyrazolonato complexes: apoptosis-promoting effects on human cancer cells. J Med Chem. 2014;57(11):4532-4542. doi:10.1021/jm500458c
• Zhao Z, Gao P, You Y, Chen T. Cancer-targeting functionalization of selenium-containing ruthenium conjugate with tumor microenvironment- responsive property to enhance theranostic effects. Chem Eur J. 2018; 24(13):3289-3298. doi:10.1002/chem.201705561
• Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP. Ruthenium(II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther. 2005;315(3):1403-1411. doi:10.1124/jpet.105.089342
• Sharma G, Rana NK, Singh P, Dubey P, Pandey DS, Koch B. P53-dependent apoptosis and cell cycle delay induced by heteroleptic complexes in human cervical cancer cells. Biomed Pharmacother. 2017; 88:218-231. doi:10.1016/j.biopha.2017.01.044
• Neves SP, de Carvalho NC, da Silva MM, et al. Ruthenium complexes containing heterocyclic thioamidates trigger caspase-mediated apoptosis through MAPK signaling in human hepatocellular carcinoma cells. Front Oncol. 2019;9:562. doi:10.3389/fonc.2019.00562
• de Carvalho NC, Neves SP, Dias RB, et al. A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1/2-mediated apoptosis in HepG2 cells through a p53-independent pathway. Cell Death Dis. 2018;9(2):1-24. doi:10.1038/s41419-017-0104-6
• Tan C, Lai S, Wu S, et al. Nuclear permeable ruthenium(II) β-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis. J Med Chem. 2010;53(21):7613-7624. doi:10.1021/jm1009296
• Berndsen RH, Weiss A, Abdul UK, et al. Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Sci Rep. 2017;7:43005. doi:10.1038/srep43005
• Lai Y, Lu N, Luo S, Wang H, Zhang P. A photoactivated sorafenib-ruthenium(II) prodrug for resistant hepatocellular carcinoma therapy through ferroptosis and purine metabolism disruption. J Med Chem. 2022;65(19):13041-13051. doi:10.1021/acs.jmedchem.2c00880
• Khan TA, Bhar K, Samanta R, et al. A bis-quinoline ruthenium(II) arene complex with submicromolar cytotoxicity in castration-resistant prostate cancer cells. Chem Commun (Camb). 2024;60(12):1579-1582. doi:10.1039/d3cc05083a
• Robles-Escajeda E, Martínez A, Varela-Ramirez A, Sánchez-Delgado RA, Aguilera RJ. Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells. Cell Biol Toxicol. 2013;29(6):431-443. doi:10.1007/s10565-013-9264-z